Additive Association of <i>ABCG2</i> rs4148155 and <i>SLC22A12</i> rs75786299 Polymorphisms with Hyperuricemia, Gout, and Nephrolithiasis: A Hospital-Based, Case-Control Study.

Kidney Dis (Basel) · 2026 · PMC12893758 · PMID 41684661

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

marginally nonsignificantp = 0.06so close (0.05 < p ≤ 0.1)

For nephrolithiasis risk, ABCG2 rs4148155 carrier had a significant association (OR = 1.16, 95% CI: 1.09 to 1.24, p < 0.0001), whereas SLC22A12 rs75786299 carrier showed a marginally nonsignificant trend (OR = 1.21, 95% CI: 0.99 to 1.48, p = 0.06), likely due to the limited number of carriers.

also in 448 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Additive Association of &lt;i&gt;ABCG2&lt;/i&gt; rs4148155 and &lt;i&gt;SLC22A12&lt;/i&gt; rs75786299 Polymorphisms with Hyperuricemia, Gout, and Nephrolithiasis: A Hospital-Based, Case-Control Study.

The sentences

Additive Association of <i>ABCG2</i> rs4148155 and <i>SLC22A12</i> rs75786299 Polymorphisms with Hyperuricemia, Gout, and Nephrolithiasis: A Hospital-Based, Case-Control Study.